Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.48 |
| ▸ | MAP2 | P11137 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857027 | 0.83 | KDM4E (0.47) | SIRT1ADRA2AADRA2BADRA2CHTR7 | |
| SCHEMBL28758655 | 0.78 | RAD52 (0.43) | MAP2RHEBPDE10AADRA2AADRA2B | |
| SCHEMBL3452904 | 0.77 | SIRT1 (0.68) | SIRT1MAP2SIRT2PDE10AADRA2A | |
| SCHEMBL992003 | 0.74 | SLC6A4 (0.46) | MAP2HTR2ASLC6A4HTR7HTR2B | |
| SCHEMBL3588222 | 0.73 | SLC6A4 (0.46) | MAP2HTR2ASLC6A4HTR7HTR2B | |
| SCHEMBL1028961 | 0.70 | SLC6A4 (0.43) | HTR2ASLC6A4 | |
| SCHEMBL3605492 | 0.69 | MAP2 (0.44) | SIRT1MAP2SIRT2 | |
| SCHEMBL1027515 | 0.66 | SLC6A4 (0.39) | HTR2ASLC6A4 | |
| SCHEMBL27380744 | 0.64 | HTR7 (0.64) | SIRT1HTR7HTR6 | |
| SCHEMBL6463083 | 0.63 | ADRA2A (0.43) | SIRT1HTR2AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2075249-B1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| EP-1597250-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| CN-100439359-C | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2008-12-03 | — | — | CN | disclosed |
| US-20060058356-A1 | Indolylmaleimide derivatives | NOVARTIS AG | 2006-03-16 | — | — | US | disclosed |
| CN-1742005-A | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2006-03-01 | — | — | CN | disclosed |
| EP-1597250-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072062-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058356-A1 | Indolylmaleimide derivatives | GSK3B, GSK3A, GSKIP | SIRT1 1759/4885MAP2 130/4885RHEB 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.